Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2023-12-25 Governance Information
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
对外担保管理制度（联交所上市后适用）
Governance Information Classification · 95% confidence The document is titled '对外担保管理制度' which translates to 'External Guarantee Management System' and details the company's policies, procedures, and internal controls regarding providing guarantees to external parties. It references compliance with company law, securities law, stock exchange listing rules, and internal governance. The content is a governance and compliance policy document rather than a financial report, announcement, or regulatory filing. It does not contain financial statements, audit results, earnings data, or voting results. It is a detailed internal governance document about managing external guarantees, which fits best under Governance Information (CGR). The document length is over 6,000 characters, indicating it is a full policy document, not a brief announcement or certification. Therefore, the appropriate classification is CGR with high confidence.
2023-12-25 Chinese
董事会薪酬与考核委员会议事规则（联交所上市后适用）
Governance Information Classification · 100% confidence The document is titled as the 'Board of Directors Remuneration and Assessment Committee Rules' for Beijing Kangle Weishi Biotechnology Co., Ltd. It details the composition, responsibilities, and procedural rules of the remuneration and assessment committee of the board. It is a governance document outlining internal rules and practices related to board and senior management compensation and assessment. There is no financial data, no report of financial results, no announcement of voting results, no legal proceedings, no capital changes, and no other regulatory filings. The content fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-12-25 Chinese
独立董事工作制度（联交所上市后适用）
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the governance structure, roles, responsibilities, qualifications, appointment, and working conditions of independent directors in the company. It references relevant laws, regulations, and stock exchange listing rules, including the Hong Kong Stock Exchange Listing Rules and Beijing Stock Exchange rules. The content is focused on governance practices and internal rules related to board members, specifically independent directors. There is no financial data, audit information, earnings, or capital structure updates. It is not a report of financial results or an announcement of voting or dividends. The document is a governance-related policy document outlining internal rules and practices for independent directors. Therefore, it fits the category of Governance Information (CGR). The document length is substantial (over 10,000 characters), indicating it is the full policy document, not just an announcement or summary. Confidence is high due to the clear focus on governance and board structure.
2023-12-25 Chinese
董事会审计委员会议事规则（联交所上市后适用）
Governance Information Classification · 95% confidence The document is titled '董事会审计委员会议事规则' which translates to 'Board Audit Committee Meeting Rules'. It outlines the composition, responsibilities, and procedural rules of the audit committee of the board of directors. It references relevant laws and stock exchange listing rules but does not contain any financial data, audit results, or report disclosures. It is a governance document detailing internal rules and committee functions rather than an audit report or financial statement. Therefore, it fits best under Governance Information (CGR). The document length is 2824 characters, which is relatively short and consistent with a governance policy document rather than a full report.
2023-12-25 Chinese
关联交易管理制度（联交所上市后适用）
Governance Information Classification · 95% confidence The document is titled '关联交易管理制度' which translates to 'Related Party Transaction Management System'. It details the company's policies, procedures, and governance regarding related party transactions, including definitions of related parties, decision-making procedures, management responsibilities, and reporting requirements. It references regulatory frameworks such as the Beijing Stock Exchange Listing Rules and the Hong Kong Listing Rules, indicating compliance and governance practices. The document is a governance and compliance manual rather than a financial report, announcement, or meeting material. It does not contain financial statements, earnings data, voting results, or transaction announcements. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2023-12-25 Chinese
第四届董事会第二十八次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 28th meeting of the 4th Board of Directors of Beijing Kangle Weishi Biotechnology Co., Ltd. The content focuses on the approval of proposals related to the issuance of H shares and listing on the Hong Kong Stock Exchange, including the issuance plan, authorization of the board to handle related matters, amendments to the company's articles of association and governance documents, appointment of auditors, and other related corporate governance matters. It includes voting results, meeting details, and descriptions of the proposals. The document is not a full financial report, earnings release, or audit report, but rather a formal announcement of board resolutions concerning capital raising and listing plans. It is not a proxy solicitation or AGM information, but a board meeting resolution announcement related to capital issuance and listing. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (over 14,000 characters) and detailed content confirm it is not a mere announcement of a report but a substantive board resolution document.
2023-12-25 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.